基酸:关于其肝脏保护作用的药理学系统审查
Haoyu Xue1, Mengjuan Wei1, Lili Ji1
1The MOE Key Laboratory for Standardization of Chinese Medicines, Shanghai Key Laboratory of Compound Chinese Medicines and The SATCM Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai 201203, China.
基酸 (CGA) 对抗各种肝脏疾病具有显著的肝脏保护作用. 这些天然化合物通过关键分子通路减少炎症和氧化应激作用.
科学领域:
- 自然产品化学 自然产品化学
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 肝脏疾病对全球的健康造成重大负担.
- 酸 (CGA) 是一种天然的多,在咖啡,茶叶和传统中医药中发现.
- 由于其潜在的肝脏保护性质,CGAs得到了认可.
研究的目的:
- 审查和分析关于CGAs肝脏保护作用的现有文献.
- 阐明CGA介导的肝脏保护的潜在机制.
主要方法:
- 在遵守PRISMA指南的基础上进行系统审查.
- 在PubMed和Web of Science数据库上进行文献搜索.
- 包括2013年至2023年3月期间发表的研究.
主要成果:
- CGAs在治疗各种肝病方面表现出有效性:药物诱导的肝损伤 (DILI),酒精性肝病 (ALD),与代谢功能障碍相关的脂肪肝病 (MAFLD),胆固醇性肝病 (CLD),肝纤维化和肝癌.
- 通过Nrf2激活和抑制TLR4/NF-κB信号传递,CGAs具有抗氧化和抗炎作用.
- 像AMPK和ERK1/2这样的关键分子,以及肠道微生物群和肠道屏障完整性,都与CGA的保护机制有关.
结论:
- 碳酸对一系列肝病具有强大的保护作用.
- 多个信号通路参与了CGAs对肝脏健康的治疗作用.
更多相关视频
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
09:03Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula
Published on: January 26, 2024
相关概念视频
Drug Distribution: Plasma Protein Binding
Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can also...
Factors Affecting Protein-Drug Binding: Protein-Related Factors
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be bound by...
Hepatic Drug Excretion: Influencing Factors
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
